Esophagogastric cancer represents a significant global health problem, with most patients
presenting with advanced-stage disease and consequently with a poor prognosis …

Cancers of the esophagus and stomach present a major health burden worldwide. In the
past 30 years we have witnessed some interesting shifts in terms of epidemiology of …

Esophageal and gastric cancer incidence has been increasing worldwide. Most cases are
diagnosed in advanced stages, and current therapy has not been able to improve the …

Amplification of the human epidermal growth factor receptor 2 (HER2) gene and
overexpression of the HER2 protein is found in 15%-20% of patients with gastric and …

Introduction: The blockade of HER2 signaling has significantly improved the outlook for
esophagogastric cancer patients. However, targeting HER2 still remains challenging due to …

The human epidermal receptor-2 (HER-2) is amplified in up to 25% of patients with
gastroesophageal adenocarcinomas. Although the presence of this amplification does not …

Opinion statement Gastric and gastroesophageal junction (GEJ) cancers represent the third
leading cause of malignancy-associated death worldwide. Approximately 15–20% of these …

Purpose: HER2 amplification occurs in 18% to 27% of gastric and gastroesophageal
junction cancers. Lapatinib, a potent ATP-competitive inhibitor simultaneously inhibits both …

HER2 expression remains an important biomarker to guide the addition of the monoclonal
antibody trastuzumab to first-line systemic chemotherapy in unresectable, metastatic …

Background Epidermal growth factor receptor (EGFR) is overexpressed in a significant
proportion of esophageal and gastric carcinomas. Although previous studies have examined …